SCHEMBL3006975

SCHEMBL3006975

CC(C)c1cc(C(C)C)c(S(=O)(=O)N2CCN(c3nc(Cc4ccc(Cl)cc4)cs3)CC2)c(C(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 2/20 0.42
DPP8 Q6V1X1 1/20 0.38
MAPT P10636 4/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 2/20 0.38
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3645260 0.94 ALDH1A1 (0.42) FABP4MAPTLMNAMAPK1SMN1; SMN2
SCHEMBL3011364 0.92 LMNA (0.38) FABP4DPP8LMNAMAPK1SMN1; SMN2
SCHEMBL3013519 0.91 OGA (0.39) FABP4DPP8MAPTLMNAMAPK1
SCHEMBL3018377 0.91 ALDH1A1 (0.40) FABP4DPP8MAPTLMNAMAPK1
SCHEMBL3650838 0.91 FABP4 (0.38) FABP4DPP8MAPTLMNAMAPK1
SCHEMBL3014217 0.91 CACNA1G (0.39) FABP4DPP8MAPTLMNAMAPK1
SCHEMBL3005463 0.91 FABP4 (0.43) FABP4DPP8MAPTLMNAMAPK1
SCHEMBL3015626 0.90 MEN1 (0.44) DPP8MAPTLMNAMAPK1SMN1; SMN2
SCHEMBL3020261 0.90 MEN1 (0.38) FABP4DPP8LMNAMAPK1SMN1; SMN2
SCHEMBL3008045 0.89 CACNA1G (0.39) FABP4DPP8MAPTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA FABP4 3254/4885DPP8 1183/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.